1. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489–495.
2. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496–501.
3. Erbel R, Haude M, Höpp HW, et al. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. N Engl J Med 1998;339:1672–1678.
4. Lee SH, Chae JK, Lee KH, et al. Full metal jackets (≥ 60 mm) of drug-eluting stents: short-and long-term clinical and angiographic outcomes. Korean Circ J 2008;38:87–94.
5. Yang TH, Hong MK, Park KH, et al. Primary sirolimus-eluting stent implantation for patients with acute ST-segment elevation myocardial infarction. Korean Circ J 2005;35:672–676.
7. Lee MG, Jeong MH, Ahn Y, et al. Comparison of paclitaxel-, sirolimus-, and zotarolimus-eluting stents in patients with acute ST-segment elevation myocardial infarction and metabolic syndrome. Circ J 2011;75:2120–2127.
8. Lee CW, Park KH, Kim YH, et al. Clinical and angiographic outcomes after placement of multiple overlapping drug-eluting stents in diffuse coronary lesions. Am J Cardiol 2006;98:918–922.
9. Lim SY, Jeong MH, Hong SJ, et al. Inflammation and delayed endothelization with overlapping drug-eluting stents in a porcine model of in-stent restenosis. Circ J 2008;72:463–468.
10. Kim W, Jeong MH, Cho JY, et al. The preventive effect on in-stent restenosis of overlapped drug-eluting stents for treating diffuse coronary artery disease. Korean Circ J 2006;36:17–23.
12. Manginas A, Gatzov P, Chasikidis C, Voudris V, Pavlides G, Cokkinos DV. Estimation of coronary flow reserve using the Thrombolysis In Myocardial Infarction (TIMI) frame count method. Am J Cardiol 1999;83:1562–1565; A7.
13. Biondi-Zoccai G, Sheiban I, Moretti C, et al. Appraising the impact of left ventricular ejection fraction on outcomes of percutaneous drug-eluting stenting for unprotected left main disease: insights from a multicenter registry of 975 patients. Clin Res Cardiol 2011;100:403–411.
14. Man SC, van der Wall EE, Swenne CA. Gated SPECT: what's the ideal method to measure LVEF? Int J Cardiovasc Imaging 2008;24:807–810.
15. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999;100:1872–1878.
17. Chevalier B, Di Mario C, Neumann FJ, et al. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial. JACC Cardiovasc Interv 2008;1:524–532.
19. Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006;48:2440–2447.
20. Kitabata H, Loh JP, Pendyala LK, et al. Safety and efficacy outcomes of overlapping second-generation everolimus-eluting stents versus first-generation drug-eluting stents. Am J Cardiol 2013;112:1093–1098.
21. Waksman R, Barbash IM, Dvir D, et al. Safety and efficacy of the XIENCE V everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice. Am J Cardiol 2012;109:1288–1294.
23. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010;375:201–209.
24. Schömig A, Dibra A, Windecker S, et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1373–1380.
26. Cho SC, Jeong MH, Kim W, et al. Clinical outcomes of everolimus- and zotarolimus-eluting stents in patients with acute myocardial infarction for small coronary artery disease. J Cardiol 2014;63:409–417.
27. Park JS, Kim YJ, Shin DG, et al. Clinical and angiographic outcome of sirolimus-eluting stent for the treatment of very long lesions. Korean Circ J 2006;36:490–494.
28. Tsagalou E, Chieffo A, Iakovou I, et al. Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery. J Am Coll Cardiol 2005;45:1570–1573.
29. Li XT, Sun H, Zhang DP, et al. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents. Coron Artery Dis 2014;25:405–411.
30. Räber L, Jüni P, Löffel L, et al. Impact of stent overlap on angiographic and long-term clinical outcome in patients undergoing drug-eluting stent implantation. J Am Coll Cardiol 2010;55:1178–1188.
31. Her SH, Yoo KD, Park CS, et al. Long-term clinical outcomes of overlapping heterogeneous drug-eluting stents compared with homogeneous drug-eluting stents. Heart 2011;97:1501–1506.
32. Kitabata H, Loh JP, Sardi GL, et al. Comparison of long-term outcomes between everolimus-eluting and sirolimus-eluting stents in small vessels. Am J Cardiol 2013;111:973–978.
33. Dvir D, Barbash IM, Torguson R, et al. Clinical outcomes after treating acute coronary syndrome patients with a drug-eluting stent: results from REWARDS-EMI (Endeavor for Myocardial Infarction Registry). Cardiovasc Revasc Med 2013;14:128–133.